Early research on AAV5-hRKp.RPGR treatment for X-linked vision disorder linked to the RPGR gene: a plain language summary

This Plain Language Summary of Publication article (PLSP) from Future Rare Diseases examines botaretigene sparoparvovec (bota-vec), an investigational gene therapy for X-linked retinitis pigmentosa (XLRP). XLRP is a severe inherited eye condition caused by mutations in the RPGR gene that lead to retinal cell degeneration and vision loss. The therapy works by delivering functional copies of the RPGR gene to potentially repair retinal damage and improve vision. The three-part clinical trial assessed different doses of bota-vec for safety and effectiveness in XLRP patients over 52 weeks.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Phase 1/2 AAV5-hRKp.RPGR (Botaretigene Sparoparvovec) Gene Therapy: Safety and Efficacy in RPGR-Associated X-Linked Retinitis Pigmentosa’ and was published in the American Journal of Ophthalmology.

Visit AJO using the link to read the original article.

• botaretigene sparoparvovec
• inherited retinal disease
• plain language summary
• retinitis pigmentosa
• retinitis pigmentosa GTPase regulator (RPGR)
• X-linked retinitis pigmentosa (XLRP)